Clinical Trial

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer

Study acronym: FESTA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-01; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2026-06-09
Trial Details
NCT Number NCT05982496
Lead Sponsor Università Vita-Salute San Raffaele
Collaborators: IRCCS San Raffaele
Conditions Breast Cancer Female, Lobular Breast Carcinoma, PET/MRI, Axillary Lymphadenopathy, Luminal A Breast Cancer
Enrollment 119 participants
Start Date 2026-06-09
Primary Completion 2029-06-15 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12